The Monash IVF (ASX:MVF) share price is gaining 6% today. Here's why

The company appears to be benefiting from Victoria lifting a ban on IVF treatments.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A couple smile as they look at a pregnancy test.

Image source: Getty Images

Key points

  • The Monash IVF share price has lifted nearly 6% today
  • It comes after COVID-19 IVF restrictions were lifted in Victoria
  • The company will resume IVF services next week

The Monash IVF Group Ltd (ASX: MVF) share price is rising today amid the lifting of a COVID-19-related suspension on IVF treatments.

The fertility services company's shares are trading at $1.052 in afternoon trade, up 5.73%.

Let's take a look at what may be impacting the company today.

Victoria IVF ban lifted

Investors appear to be reacting positively to news the company will be able to recommence fertility services. The Victorian State Government lifted a temporary ban on IVF procedures today.

The order had originally slated IVF procedures to remain suspended until 12 April due to COVID-19 restrictions on non-urgent surgeries.

Today, however, the government reversed this decision which will enable IVF procedures to recommence. Monash IVF says it will recommence its IVF services by 26 January.

An online petition calling for a reversal of the suspension of fertility treatments across Victoria gained 140.000 signatures, 7News reported.

In a statement released to the ASX, Monash IVF stated:

Monash IVF is pleased IVF procedures will recommence and the company is focussed on informing patients of their options to recommence their treatment and ensure sufficient workforce and resources are in place to meet demand.

The company also remains focussed on maintaining appropriate measures and protocols in place to protect the health and safety of the company's patients, employees and specialists.

Monash IVF shares have seen consistent gains in the past year. In November, the company released its financial results for FY 2021, which showed adjusted net profit after tax soared 61.5% compared to the previous financial year.

Monash IVF share price snapshot

The Monash IVF share price has soared around 42% in the past year but is flat this year to date.

In contrast, the S&P/ASX 200 Index (ASX: XJO) has returned about 8% in the past 12 months.

Monash IVF has a market capitalisation of about $409 million based on its current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Female scientist working in a laboratory.
Healthcare Shares

Down almost 20% this year, how high could Mesoblast shares go?

The forward pipeline is looking promising.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Down 38% this year, is it finally time to buy low on CSL, ResMed and Pro Medicus shares?

These three stocks might be too cheap to ignore.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

How much would $10,000 become if CSL shares returned to their record high?

After a sharp decline, CSL is in a new phase. The question is what happens next.

Read more »

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »

A smiling businessman sits at a desk with bags of mony, indicating a share price rise after funding has been approved
Healthcare Shares

Telix Pharmaceuticals upsizes convertible bonds to US$600 million

Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds.

Read more »